Therapeutisches Management bei Vitiligo.

Area of Science:

• Dermatology
• Immunology
• Genetics

Background:

• Vitiligo is an acquired skin disorder affecting 0.5% of the global population.
• It causes patchy depigmentation, leading to significant cosmetic disfigurement and psychological distress.
• Pathophysiology involves genetic predisposition, autoimmune mechanisms, and oxidative stress contributing to melanocyte loss.

Purpose of the Study:

• To present European treatment guidelines and recommendations from recent reviews for vitiligo.
• To outline current therapeutic strategies targeting the key pathophysiological mechanisms of vitiligo.
• To emphasize the importance of early intervention and combination therapies for optimal outcomes.

Main Methods:

• Review of European treatment guidelines and current literature on vitiligo.
• Categorization of therapies based on their mechanism of action: immune modulation, oxidative stress reduction, and melanocyte regeneration.
• Inclusion of supportive measures like camouflage techniques and relapse prevention strategies.

Main Results:

• Therapeutic options include immunomodulators (corticosteroids, calcineurin inhibitors), antioxidants, phototherapy (UVB), and melanocyte transplantation.
• Combination therapies are generally more effective than monotherapies.
• Early treatment initiation improves prognosis, aiming to halt disease progression, stabilize depigmented areas, and achieve repigmentation.

Conclusions:

• Current therapeutic approaches can halt vitiligo progression, stabilize depigmentation, and promote repigmentation.
• Relapse prophylaxis with calcineurin inhibitors is recommended after successful repigmentation.
• Ongoing research into vitiligo pathogenesis offers hope for novel future therapies.